# KingCreate Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kingcreate-biotechnology

- Industry: Medical Devices & Equipment
- Headquarters: Guangzhou, China
- Website: www.kingcreate.com.cn
- Total disclosed funding: $15M
- Latest round: Series C (Aug 20, 2023)
- Investors on record: 6

## About

Established in 2016 and based in Guangzhou, China, Yunjing operates as a biotechnology company that provides precision medical in vitro diagnostic products. The company cooperates with illumina, Nayo Lab and Henan Cancer Hospital, etc. It covers an area of about 3300 square feet and has over 2500 square feet of instrument production workshop, reagent production workshop, QC production workshop, testing laboratory and R&D laboratory. In April 2020, the company promoted the Desktop High-Throughput Sequencer with Illumina. In October 2021, it was awarded the title of "2021 Guangzhou Future Unicorn Innovative Enterprise". In August 2023, the company closed series C funding led by SJ Jiacheng Investment Management, with participation from Aurora Private Equity and Legend Capital.

The company provides tNGS (targeted sequencing) technology platforms and molecular diagnostics solutions. Its product mainly includes medical devices, including KM MiniSeqDx-CN, liquid-based cell and lung cancer kit. And it has many clinical trial products, such as lung cancer rayon 11 gene organized version and colorectal cancer raytek 10 gene tissue version.

## Funding rounds

- Series C, Aug 20, 2023 — Legend Capital, Aurora Private Equity, Shanghai Shengjing Jiacheng Venture Capital Management
- Series B, Dec 25, 2020, $15M — Legend Capital, E Fund Management Co.,Ltd
- Series A, Dec 1, 2019 — Legend Capital, China Development Bank Capital, Shiyu Capital

## Investors

- Legend Capital — Series A, Series B, Series C
- China Development Bank Capital — Series A
- Shiyu Capital (https://capitalatlas.ai/funds/shiyu-capital) — Series A
- E Fund Management Co.,Ltd — Series B
- Aurora Private Equity (https://capitalatlas.ai/funds/aurora-private-equity) — Series C
- Shanghai Shengjing Jiacheng Venture Capital Management — Series C